- Home
- BVFL vs AVTX Comparison
BVFL vs AVTX Comparison
Compare BVFL & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- AVTX
- Stock Information
- Founded
- BVFL 1873
- AVTX 2011
- Country
- BVFL United States
- AVTX United States
- Employees
- BVFL N/A
- AVTX N/A
- Industry
- BVFL Savings Institutions
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BVFL Finance
- AVTX Health Care
- Exchange
- BVFL Nasdaq
- AVTX Nasdaq
- Market Cap
- BVFL 150.2M
- AVTX 138.8M
- IPO Year
- BVFL N/A
- AVTX 2015
- Fundamental
- Price
- BVFL $16.67
- AVTX $11.60
- Analyst Decision
- BVFL
- AVTX Strong Buy
- Analyst Count
- BVFL 0
- AVTX 8
- Target Price
- BVFL N/A
- AVTX $31.00
- AVG Volume (30 Days)
- BVFL 46.0K
- AVTX 230.1K
- Earning Date
- BVFL 10-20-2025
- AVTX 11-06-2025
- Dividend Yield
- BVFL N/A
- AVTX N/A
- EPS Growth
- BVFL 27.09
- AVTX N/A
- EPS
- BVFL 1.07
- AVTX N/A
- Revenue
- BVFL $38,333,000.00
- AVTX $441,000.00
- Revenue This Year
- BVFL N/A
- AVTX N/A
- Revenue Next Year
- BVFL N/A
- AVTX N/A
- P/E Ratio
- BVFL $15.55
- AVTX N/A
- Revenue Growth
- BVFL 2.48
- AVTX N/A
- 52 Week Low
- BVFL $13.53
- AVTX $3.39
- 52 Week High
- BVFL $18.19
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- BVFL 60.58
- AVTX 74.04
- Support Level
- BVFL $16.63
- AVTX $8.65
- Resistance Level
- BVFL $16.90
- AVTX $12.41
- Average True Range (ATR)
- BVFL 0.20
- AVTX 0.86
- MACD
- BVFL -0.02
- AVTX 0.11
- Stochastic Oscillator
- BVFL 49.35
- AVTX 81.00
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).